OptimizeRx Corporation (OPRX)
After hours:
| Previous Close | 12.85 |
| Open | 12.87 |
| Bid | 12.67 x 200 |
| Ask | 12.76 x 200 |
| Day's Range | 12.50 - 13.01 |
| 52 Week Range | 6.92 - 16.65 |
| Volume | |
| Avg. Volume | 149,730 |
| Market Cap | 230.754M |
| Beta (5Y Monthly) | 1.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.04 |
| Earnings Date | Aug 12, 2024 - Aug 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.33 |
GlobeNewswireOptimizeRx Reports First Quarter 2024 Financial Results
Q1 revenue of $19.7 million, increasing 51% year-over-yearQ1 gross profit increased 64% year-over-year to $12.2 million with a gross margin of 62%Won 9 DAAP deals during Q1 WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended March 31, 2024. Quarterly comparis
ZacksDoes OptimizeRx (OPRX) Have the Potential to Rally 34.78% as Wall Street Analysts Expect?
The consensus price target hints at a 34.8% upside potential for OptimizeRx (OPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- GlobeNewswire
OptimizeRx to Participate in Upcoming Investor Conferences
WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: RBC Capital Markets Global Healthcare Conference, New York City, May 14 – 15, 2024B.Riley Securities 24th Annual Institutional Investor Conference, Beverly
